Charleston, SC -- (SBWIRE) -- 12/19/2013 -- Hot Shot Stock Alerts is a market and commodities news and marketing web service, providing investing news, business news, headline news, news alerts, personal finance, stock market, and press releases. Hot Shot Stock Alerts carries you the most fascinating reviews and research reports regarding following stocks: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Amgen, Inc. (NASDAQ:AMGN), Opexa Therapeutics Inc (NASDAQ:OPXA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed latest trading day at $5.58, up +1.09%, on volume of over 4.11 million shares. The stock fell -6.22% in the last 5 days. Its average trading volume is 5.55 million shares. In the time frame of the last one month, the share-price has surged almost +0.09%. Its market capitalization was $1.22 billion.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
For How Long ARNA will Fight for Profitability? Read This Trend Analysis report
With the latest rise of +8.41%, NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) now has YTD performance +196.04% which for the week is positive at +18.99%. The total number of shares traded on the latest trading day was about 4.10M shares, and changed hands at price range of $24.84 to $27.28 apiece. The company ended previous trading at $26.94.
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.
Will NPSP Continue To Move Higher? Find Out Here
Amgen, Inc. (NASDAQ:AMGN) reported the price of the stock moved up +1.56% and finished the day at $112.73 on above average volume. The total number of shares traded on the latest trading day was about 4.04M shares, and changed hands at price range of $109.71 to $112.75 apiece. The shares rushed about +30.78% since the start of year and has a -4.08% lost in last three months. Narrowing down the performance period, the stock fell -2.84% for the month and a -0.28% drop over the week.
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada.
Why Should Investors Buy AMGN After The Recent Gain? Just Go Here and Find Out
Opexa Therapeutics Inc (NASDAQ:OPXA) ended previous trading at $1.68, losing -10.64%. The total number of shares traded on the latest trading day was about 3.59M shares. In the last 5 days it showed a drop of -16.83% and on its one month graph, shares are -25.66% down. The stock has a 52-week high price of $5.19 and its 52-week low was recorded at $1.07.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology.
Will OPXA Get Buyers Even After The Recent Fall? Find Out Here
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list.
Never invest into a stock discussed on this web site or the HotShotStockAlerts.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
HotShotStockAlerts.com is owned and operated by FlipVentures LLC. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Read full Disclaimer at: http://hotshotstockalerts.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)